STOCK TITAN

Novocure to Report Third Quarter 2024 Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Novocure (NASDAQ: NVCR) has announced that it will release its third quarter 2024 financial results on Wednesday, October 30, 2024, before the U.S. financial markets open. The company's management will host a conference call and webcast at 8:00 a.m. EDT on the same day to discuss the financial results for the three-month quarter and first nine months ending September 30, 2024.

Investors can access the conference call via a registration link that will provide dial-in details. A separate webcast registration link is available for those who prefer to join online. Presentation slides and the corporate presentation will be accessible from Novocure's Investor Relations webpage and will remain available for at least 14 days after the call.

Novocure (NASDAQ: NVCR) ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 mercoledì, 30 ottobre 2024, prima dell'apertura dei mercati finanziari statunitensi. La direzione dell'azienda ospiterà una conferenza telefonica e una diretta streaming alle 8:00 EDT lo stesso giorno per discutere i risultati finanziari del trimestre di tre mesi e dei primi nove mesi che si concludono il 30 settembre 2024.

Gli investitori possono accedere alla conferenza telefonica tramite un link di registrazione che fornirà i dettagli per la chiamata. Un link di registrazione separato per la diretta streaming è disponibile per coloro che preferiscono unirsi online. Le diapositive di presentazione e la presentazione aziendale saranno accessibili dalla pagina web delle Relazioni con gli Investitori di Novocure e rimarranno disponibili per almeno 14 giorni dopo la call.

Novocure (NASDAQ: NVCR) ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 el miércoles 30 de octubre de 2024, antes de la apertura de los mercados financieros en EE.UU. La dirección de la empresa organizará una llamada de conferencia y transmisión en vivo a las 8:00 a.m. EDT el mismo día para discutir los resultados financieros del trimestre de tres meses y de los primeros nueve meses que finalizan el 30 de septiembre de 2024.

Los inversores pueden acceder a la llamada de conferencia a través de un enlace de registro que proporcionará los detalles de la llamada. Un enlace de registro de transmisión en vivo separado está disponible para aquellos que prefieren unirse en línea. Las diapositivas de la presentación y la presentación corporativa estarán accesibles desde la página web de Relaciones con Inversores de Novocure y estarán disponibles durante al menos 14 días después de la llamada.

노보큐어(NASDAQ: NVCR)는 2024년 3분기 재무 결과2024년 10월 30일 수요일에 미국 금융 시장이 열리기 전에 발표할 예정이라고 발표했습니다. 회사의 경영진은 같은 날 오전 8시 EDT에 컨퍼런스 콜과 웹캐스트를 진행하여 2024년 9월 30일 종료된 3개월 분기 및 처음 9개월의 재무 결과에 대해 논의할 것입니다.

투자자는 전화 회의에 등록 링크를 통해 접속할 수 있으며, 이는 전화 걸기 세부 정보를 제공합니다. 온라인으로 참여하기를 원하는 경우 별도의 웹캐스트 등록 링크가 제공됩니다. 발표 슬라이드 및 기업 프레젠테이션은 노보큐어의 투자자 관계 웹페이지에서 접근 가능하며, 통화 후 최소 14일 동안 이용할 수 있습니다.

Novocure (NASDAQ: NVCR) a annoncé qu'il publiera ses résultats financiers du troisième trimestre 2024 le mercredi 30 octobre 2024, avant l'ouverture des marchés financiers aux États-Unis. La direction de l'entreprise animera un appel conférence et un webinaire à 8h00 EDT le même jour pour discuter des résultats financiers du trimestre de trois mois et des neuf premiers mois se terminant le 30 septembre 2024.

Les investisseurs peuvent accéder à l'appel conférence via un lien d'inscription qui fournira les détails de connexion. Un lien d'inscription séparé pour le webinaire est disponible pour ceux qui préfèrent se joindre en ligne. Les diapositives de présentation et la présentation d'entreprise seront accessibles depuis la page des Relations Investisseurs de Novocure et resteront disponibles pendant au moins 14 jours après l'appel.

Novocure (NASDAQ: NVCR) hat bekannt gegeben, dass es seine finanziellen Ergebnisse für das dritte Quartal 2024 am Mittwoch, den 30. Oktober 2024, vor der Eröffnung der US-Finanzmärkte veröffentlichen wird. Das Management des Unternehmens wird am selben Tag um 8:00 Uhr EDT eine Telefonkonferenz und einen Webcast veranstalten, um die finanziellen Ergebnisse für das dreimonatige Quartal und die ersten neun Monate bis zum 30. September 2024 zu besprechen.

Investoren können auf die Telefonkonferenz über einen Registrierungslink zugreifen, der die Einwahldaten bereitstellt. Ein separater Registrierungslink für den Webcast steht für diejenigen zur Verfügung, die lieber online teilnehmen möchten. Präsentationsfolien und die Unternehmenspräsentation sind auf der Investor-Relations-Webseite von Novocure zugänglich und werden mindestens 14 Tage nach der Konferenz verfügbar bleiben.

Positive
  • None.
Negative
  • None.

ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 30, to discuss the company’s financial results for the three-month quarter and first nine months of the year that ended September 30, 2024.

To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link.

The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “could” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 22, 2024, and subsequent filings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Investors:

Ingrid Goldberg

investorinfo@novocure.com

Media:

Catherine Falcetti

media@novocure.com

Source: Novocure

FAQ

When will Novocure (NVCR) report its Q3 2024 financial results?

Novocure (NVCR) will report its third quarter 2024 financial results on Wednesday, October 30, 2024, before the U.S. financial markets open.

What time is Novocure's (NVCR) Q3 2024 earnings conference call?

Novocure's (NVCR) Q3 2024 earnings conference call and webcast is scheduled for 8:00 a.m. EDT on October 30, 2024.

How can investors access Novocure's (NVCR) Q3 2024 earnings call?

Investors can access Novocure's (NVCR) Q3 2024 earnings call by using the provided conference call registration link for phone access or the webcast registration link for online participation.

Where can I find Novocure's (NVCR) Q3 2024 earnings presentation slides?

Novocure's (NVCR) Q3 2024 earnings presentation slides will be available on the Investor Relations page of Novocure's website, www.novocure.com/investor-relations, and will remain accessible for at least 14 days following the call.

NovoCure Limited Ordinary Shares

NASDAQ:NVCR

NVCR Rankings

NVCR Latest News

NVCR Stock Data

1.88B
97.93M
9.26%
86.65%
5.5%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
ST. HELIER